crotalidae polyvalent immune fab ovine sold brandname crofab snake antivenin indicated north american crotalid rattlesnake copperhead cottonmouthwater moccasin snake crofab composed several monovalent fragment antigenbinding proteins fab derived blood sheep immunized one four snake venom crotalus atrox western diamondback rattlesnake crotalus adamanteus eastern diamondback rattlesnake crotalus scutulatus mojave rattlesnake agkistrodon piscivorus cottonmouth water moccasin monospecific antivenin purified sheep serum digested enzyme papain purified resulting specific fab fragments resulting four different fab preparations mixed formulate final product production technology invented drs john sullivan findlay developed clinically via multicenter clinical trials united commercialized btg limited formerly protherics plc reported washington post july commercially available antivenin united states treatment venomous snakebites release competing product anavip crotalid snakebites range mild lifethreatening depending size type snake amount venom injected location bite turn determines number vials crofab required patient untreated snake venom cause severe pain tissue damage result loss limb even death prompt within six hours snake bite treatment crofab recommended fab refers fragment antigenbinding active mechanism antivenom common adverse events reported clinical studies mild moderate reactions involving skin appendages primarily urticaria rash pruritus occurred patients three patients experienced serious adverse event two patients severe allergic reaction severe hives severe rash pruritus following treatment one patient recurrent coagulopathy due envenomation required rehospitalisation additional antivenin administration clinical trials recurrent coagulopathy return coagulation abnormality successfully treated antivenin characterised decreased fibrinogen decreased platelets elevated prothrombin time occurred approximately half patients studied recurrent coagulopathy may persist one two weeks one patient discontinued crofab therapy due allergic reaction patients allergies papain chymopapain papaya extracts pineapple enzyme bromelain may also risk allergic reaction leslie boyer director viper institute team developed crofab said crestfallen discover wholesale price anascorp latest antivenom high cost effective even treatment critically ill children industry website fierce pharma called product drug launch disaster one bizarre marketing tales industry boyer said crofab us drug whose sister product retailed mexico resulting bills arizona patients per vial one person rejected treatment died couldnt afford pay boyer collected data cost production marketing found largest true cost payers legal regulatory hospital activities involved selling drug clinical trials contributed paid government grants costs httpsenwikipediaorgwikicrotalidaepolyvalentimmunefab